ArticleMedical oncology (Northwood, London, England)2012
Correlation of major histocompatibility complex class I related A (MICA) polymorphism with the risk of developing breast cancer.
Article in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Association of the CXCL12 rs1801157 Polymorphism with Breast Cancer Risk: A Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2024Pooled it
- Association between MICA rs2596542 Polymorphism with the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients.Pathology oncology research : POR · 2020Article
- MICA polymorphisms and cancer risk: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- MHC class I chain-related gene a diversity in patients with cutaneous malignant melanoma from southeastern Spain.Disease markers · 2015Article
- A variant upstream of HLA-DRB1 and multiple variants in MICA influence susceptibility to cervical cancer in a Swedish population.Cancer medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, we examined the association of different alleles of MICA gene with the risk of breast cancer development in Iranian population. Our data showed a significant relationship between longer alleles, alleles with 9- and 6-GCT repeat of MICA gene, and a higher risk of developing breast cancer according to the age of onset. The data indicated a 6-fold increase for developing breast cancer in patients carrying the allele with 6-GCT repeat after age 50 (OR = 5.8333, 95% CI: 1.2976-26/2236, P = 0.0172). In addition, patients carrying longer alleles in their genotype (6/6, 6/9, and 9/9 genotypes) were found significantly at higher risk of developing breast cancer than control individuals (OR = 5.6, P = 0.0038, 95% CI: 1.6578-18.9166). In contrast, alleles with short GCT repeat of 4 and 5.1 showed to play a role in reducing the risk of breast cancer (OR = 0.79, P = 0.3643 and 95% CI: 0.4743-1.3157). Women with allele 4 were found twofold more protected against breast cancer (OR = 0.4597, 95% CI: 0.2164-0.9765, P = 0.0401). The results suggested that women with genotypes with 9- and 6-GCT repeat alleles of MICA gene could be considered more potent to develop breast cancer especially at higher age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.